ArticleIranian journal of biotechnology2021
Transdermal Co-Delivery of Urea and Recombinant Human Growth Hormone.
Article in Iranian journal of biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Tracking the Effect of Phosvitin (PV) Concentration on the Skin Permeation of Somatotropin (STH) from Semi-Solid Hydrogel Formulations.Polymers · 2025Article
- A Comprehensive Review on Potential Chemical and Herbal Permeation Enhancers Used in Transdermal Drug Delivery Systems.Recent advances in drug delivery and formulation · 2024Review
- Natural Ingredients of Transdermal Drug Delivery Systems as Permeation Enhancers of Active Substances through theMolecular pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Urea with super-hydrating and moisturizing properties is mainly used as an adjunctive treatment of diseases associated with dry skin. In this regard, the recombinant human growth hormone (rhGH) with rejuvenating properties is used as a base material in beauty creams. Although urea easily passes through the skin, the epidermal skin barrier restricts the passage of hGH due to its size. Objective: in this research, in order to solve this problem, hydroxy propyl-beta cyclodextrin (HP-β-CD) is used as a soluble chemical enhancer. Material and Methods: UV and circular dichroism spectroscopy were used for the investigation of structural modification. The permeation process was studied in vitro on rat skin using vertical Franz diffusion cells. Enzyme-linked immunosorbent assay were used for rhGH activity assessment and evaluation of transdermal delivery. Results: First, due to the denaturing effects of urea on proteins its concentration was optimized to maintain biological structure and protein activity. UV spectroscopy and CD data proved that the secondary structure of rhGH is preserved in the presence of urea (0.5-2 M) and HP-β-CD, which elevates urea and rhGH permeation. Maximum permeability was observed at 120 min after sampling (1424.35 ng.ml.cm Conclusion: According to results, this strategy can be considered as a successful method for enhanced Co-delivery of rhGH and urea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.